Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$31.82 USD
-0.31 (-0.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $31.83 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.82 USD
-0.31 (-0.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $31.83 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Best Momentum Stocks to Buy for August 8th
by Zacks Equity Research
CLH, NETI and SUPN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2022.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last?
by Zacks Equity Research
Supernus (SUPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Supernus (SUPN)
by Zacks Equity Research
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 90.48% and 5.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree
by Zacks Equity Research
The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.
Supernus Pharmaceuticals (SUPN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 152.94% and 4.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust Small Cap Value AlphaDEX ETF (FYT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYT
Should First Trust Small Cap Value AlphaDEX ETF (FYT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYT
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -57.69% and -0.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus (SUPN) Receives FDA Approval for ADHD Treatment
by Zacks Equity Research
Supernus (SUPN) gets FDA approval for ADHD treatment, Qelbree, in pediatric patients 6 to 17 years of age.
Company News for Dec 24, 2020
by Zacks Equity Research
Companies in the news are: SUPN, PLTR, JAGX, SRNE
Is Supernus Pharmaceuticals (SUPN) a Worthy Stock Now?
by Zacks Equity Research
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
Company News for Nov 5, 2020
by Zacks Equity Research
Companies In The News Are: CLH, HLT, RDWR, SUPN
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Supernus (SUPN) This Earnings Season?
by Zacks Equity Research
Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.
Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.
Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.
Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.